1 |
马书梅, 刘瑞娟, 张影影. 肺癌的流行病学[J]. 世界最新医学信息文摘, 2019, 19(26): 77-78, 80.
|
2 |
YASMIN R, SIRAJ S, HASSAN A, et al. Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies [J]. Mediators Inflamm, 2015, 2015:201703.
|
3 |
SETO E, YOSHIDA M. Erasers of histone acetylation: the histone deacetylase enzymes [J]. Cold Spring Harb Perspect Biol, 2014, 6(4): a018713.
|
4 |
OKUDELA K, MITSUI H, SUZUKI T, et al. Expression of HDAC9 in lung cancer:potential role in lung carcinogenesis [J]. Int J Clin Exp Pathol, 2014, 7(1): 213-220.
|
5 |
FALKENBERG K J, JOHNSTONE R W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders [J]. Nat Rev Drug Discov, 2014, 13(9): 673-691.
|
6 |
SURAWEERA A, O’BYRNE K J, RICHARD D J, et al. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi [J]. Front Oncol, 2018, 8:92.
|
7 |
MCMILLAN M T, OJERHOLM E, VERMA V, et al. Radiation treatment time and overall survival in locally advanced non-small cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2017, 98(5): 1142-1152.
|
8 |
HESSMANN E, JOHNSEN S A, SIVEKE J T, et al. Epigenetic treatment of pancreatic cancer: Is there a therapeutic perspective on the horizon? [J]. Gut, 2017, 66(1):168-179.
|
9 |
BAO L M,DIAO H,DONG N, et al. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation [J]. Cell Biol Toxicol, 2016, 32(6): 469-482.
|
10 |
FISCHER C, LEITHNER K, WOHLKOENIG C, et al. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization [J]. Mol Cancer, 2015, 14: 4.
|
11 |
TO K K, TONG W S, FU L W. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat [J]. Lung Cancer, 2017, 103: 58-65.
|
12 |
MINAMIYA Y, ONO T, SAITO H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung[J]. Lung Cancer, 2011, 74(2): 300-304.
|
13 |
OSADA H, TATEMATSU Y, SAITO H, et al. Reduced expression of class Ⅱ histone deacetylase genes is associated with poor prognosis in lung cancer patients [J]. Int J Cancer, 2004, 112(1): 26-32.
|
14 |
ZHANG Q C, JIANG S J, ZHANG S, et al. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line [J]. Asian Pac J Cancer Prev, 2012, 13(7): 3471-3476.
|
15 |
GROSELJ B, SHARMA N L, HAMDY F C, et al. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair [J]. Br J Cancer, 2013, 108(4): 748-754.
|
16 |
ADIMOOLAM S, SIRISAWAD M, CHEN J, et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination [J]. Procl Natl Acad Sci USA, 2007, 104 (49): 19482-19487.
|
17 |
MCMILLAN M T, OJERHOLM E, VERMA V, et al. Radiation treatment time and overall survival in locally advanced non-small cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2017, 98(5): 1142-1152.
|
18 |
JIN X F, WU N N, DAI J J, et al. TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4-phenylbutyrate treatment [J]. Cancer Med,2017, 6(2): 424-438.
|
19 |
LI L, SUN Y, LIU J, et al. Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells [J]. BMC Biochem, 2015, 16(1): 2.
|
20 |
BOURKE E, BROWN J A,TAKEDA S, et al. DNA damage induces Chk1-dependent threonine-160 phosphorylation and activation of Cdk2 [J]. Oncogene, 2010, 29(4): 616-624.
|
21 |
敖经盛, 鲍志荣, 全 红. 纳米复合材料GO@AgPt对非小细胞肺癌的放射增敏作用[J].中国医学物理学杂志,2020,37(4): 514-519.
|
22 |
TAILOR D,HAHM E R,KALE R K, et al. Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells [J]. Mitochondrian, 2014, 16: 55-64.
|
23 |
MAHA S A, KAREM H A, SAIED A J, et al. The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells [J]. Clin Pharmacol, 2018,10: 135-140.
|
24 |
RIVERA S,LETEUR C,MEGNIN F, et al. Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat [J]. Oncotarget, 2017, 8(34): 56210-56227.
|